AlphaMadera's AlphaVal page computes Sanofi's fair value using a multi-method blend (DCF, comparable-multiples, and Graham-style intrinsic value), then compares it to the current market price to flag SNY as undervalued, fairly valued, or overvalued.

What is Sanofi's fair value?

Fair value for SNY is a model output combining discounted cash flow projections, peer-group multiples, and a Graham number floor. The live AlphaVal page shows the blended fair value alongside each method's individual estimate.

How does AlphaMadera value SNY?

AlphaVal uses three primary techniques: a five-year discounted-cash-flow projection with terminal multiple, peer-group multiple analysis (P/E, EV/EBITDA, P/S), and Graham's defensive-investor intrinsic-value formula. Inputs come from SNY's most recent reported fundamentals.

SNY - Sanofi

Price: -- -- | CONSENSUS: Hold DETAILS | PRICE TARGET: $49.50 DETAILS

AlphaVal

Deterministic, archetype-aware fair value

Stable Earnings Power 80% confidence

Primary model: P/Adj-EPS × Normalized Multiple

Valuation Signal Undervalued Moderate

Trading 26.2% below fair value

Current Price $45.28

Bear Case $52.58 16.1% upside ($52.58 - $45.28) / $45.28 = 16.1% $4.66 × 12x P/E

Fair Value $61.34 35.5% upside ($61.34 - $45.28) / $45.28 = 35.5% $4.66 × 14x P/E

Bull Case $70.10 54.8% upside ($70.10 - $45.28) / $45.28 = 54.8% $4.66 × 16x P/E

Adjust Assumptions

P/E Multiple

14.0x

Adjusted EPS

4.66$

Key Value Driver

Normalized P/E multiple (14x base case)

Implied Market Multiple 9.7x

Plain-Language Summary

Our base-case estimate uses a valuation based on adjusted earnings per share and a normalized price-to-earnings multiple. We then blend that result with the average analyst price target of $49.50 from 27 analysts, using a 25% weight on analyst consensus. That produces an estimated intrinsic value of $61.34 per share.

Warnings

⚠ The company pays out 235% of its profits as dividends. That leaves little cushion — the dividend could be cut if business slows down.

ℹ Wall Street's average price target is $49.50 (from 27 analysts). Our estimate is 32% above the consensus -- consider that gap carefully.

ℹ Financial statements were converted from EUR into USD using EURUSD at 1.1387 USD per EUR.

Key Risks

Growth DCF inappropriate — terminal value assumptions dominate
EV/EBITDA misleading for regulated businesses where capex is mandated
Regulatory risk is a fat tail not visible in normal multiples